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A B S T R A C T
Objective: To determine the prevalence of resistance to rifampicin alone; rifampicin and isoniazid, and
second-line anti-TB drugs among sputum smear-positive tuberculosis patients in Zimbabwe.
Design: A health facility-based cross-sectional survey.
Results: In total, 1114 (87.6%) new and 158 (12.4%) retreatment TB patients were enrolled. MTB was
conﬁrmed by Xpert MTB/RIF among 1184 (93%) smear-positive sputum samples. There were 64 samples
with Xpert MTB/RIF-determined rifampicin resistance. However, two were rifampicin susceptible on
phenotypic drug susceptibility testing. The prevalence of RR-TB was [4.0% (95% CI, 2.9, 5.4%), n = 42/1043)
and 14.2% (95% CI, 8.9, 21.1%; n = 20/141) among new and retreatment patients, respectively. The
prevalence of MDR-TB was 2.0% (95% CI, 1.3, 3.1%) and 6.4% (95% CI, 2.4, 10.3%) among new and
retreatment TB patients, respectively. Risk factors for RR-TB included prior TB treatment, self-reported
HIV infection, travel outside Zimbabwe for one month (univariate), and age <15 years. Having at least a
secondary education was protective against RR-TB.
Conclusion: The prevalence of MDR-TB in Zimbabwe has remained stable since the 1994 subnational
survey. However, the prevalence of rifampicin mono-resistance was double that of MDR-TB.
© 2019 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
In the modern era, Mycobacterium tuberculosis (MTB) drug
resistance is among the key challenges in ending TB (Mariandyshev
and Eliseev 2017). In 2016, there were 600 000 new cases globally
of multi-drug resistant tuberculosis (MDR-TB), deﬁned as resis-
tance to at least isoniazid and rifampicin (RIF), resulting in an
estimated quarter-million annual deaths (World Health Organisa-
tion 2016). An estimated 92 629 MDR-TB cases (approximately 16%
of the global burden) occurred on the African continent. However,
70% of these were not notiﬁed to health authorities, and only one-
half of the countries have completed a formal drug resistance
survey (DRS) (World Health Organisation 2017).
Although neighboring South Africa reports the second highest
absolute number of notiﬁed rifampicin-resistant cases in the world
(second only to India) (World Health Organisation 2015b), and
studies from the north of Zimbabwe have indicated a possible
increase in MDR-TB prevalence among retreatment cases (Metcalfe
et al. 2014), no nationally representative DRS has been performed
in Zimbabwe. In 1994 a sub-national DRS was conducted in
Zimbabwe and the prevalence of MDR-TB was 1.9% (95% CI, 1.1, 3.2)
and 8.3% (95% CI, 2.9, 21.8) among new and retreatment TB
patients, respectively (Mwinga 2006). At this time in the mid-
1990s, HIV was rapidly becoming hyperendemic in Zimbabwe
(Harries et al. 2001), and standard “short-course” 6-month
regimens including RIF were yet to be adopted (this was done
in 1994), antiretroviral drugs (ARVs) were unavailable, and it was
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questioned whether the societal costs of treating MDR-TB was
worth control of the relatively small risk it presented (Schaaf et al.
1996). Since that time, there have been dramatic changes to the TB
diagnostic and MDR-TB treatment landscapes; substantial
increases in movement of economic and political migrants across
borders in the Southern African region; and rapid and sustained
scale-up of ARVs.
The best estimates of the burden of drug resistant TB in Africa
require well-performed, population-based survey ﬁndings (Ismail
et al. 2018). We undertook a cross-sectional survey in 2015–2016 to
determine the prevalence among new and retreatment TB cases of
Rifampicin-mono-resistance, MDR-TB, and resistance to second-
line agents among those with MDR-TB. We also sought to assess
the risk factors for rifampicin-resistant TB and to compare the
MDR-TB estimate to that obtained in 1994 as a measure of the
burden of drug-resistant TB.
Methods
Study design
A population-based cross-sectional study. Initially, patients in
sampled health facilities were screened and diagnosed for TB using
smear microscopy. Those who were smear-positive were asked to
enroll in the survey as per WHO guidelines (World Health
Organisation 2015a). The survey was conducted from August
2015-September 2016 on sputum-positive new and retreatment TB
patients, regardless of age or HIV status, and not already on anti-TB
therapy.
Since rifampicin resistance has conventionally been considered
a proxy for MDR, and due to resource constraints, only Xpert MTB/
RIF-determined rifampicin-resistant (RR) specimens proceeded to
solid culture and ﬁrst- and second-line DST. All patients whose
samples had RR-TB strains on Xpert were re-interviewed to verify
history of TB treatment.
Survey procedures
A survey questionnaire eliciting socio-demographic and clinical
information (e.g. self-reported HIV status and history of TB) was
administered to all consenting participants at enrolment. Two
spot-sputum specimens were collected from consenting patients
within two days of a smear-positive TB diagnosis. Sputum
collection was done under the supervision of trained nurses.
About 5 mL of spot-sputum specimens were collected in two 50 mL
screw-capped falcon tubes, each containing 5 mL of Cetyl-
Pyridium-Chloride. This was done to maintain the integrity of
the sample in case of delays (of up to 30 days) in sample
transportation to the National Reference Laboratory. Each tube was
labelled with a unique patient identiﬁcation number (PIN). The
specimens were triple-packaged in zip-lock bags to minimize
spillage and contamination and were stored at room temperature.
A private courier transported the specimens to the National TB
Reference Laboratory (NTBRL).
At the NTBRL, both specimens were vortexed for 15 s, pooled,
and then split again. One specimen was tested using the Xpert
MTB/RIF assay and the other was archived. A barcode reader was
used to minimize transcription errors when inputting PIN
numbers. In case of errors, assays were repeated using the
remaining specimens from ﬁrst specimens. Subsequent proce-
dures were based upon Xpert MTB/RIF results: if RR-TB was not
detected or MTB was not detected, no further procedures were
performed. If RR-TB was detected, archived specimens were
retrieved, decontaminated and the resultant sputum deposits
were inoculated on LJ and pyruvate agar media according to
standard operating procedures (Stop TB Partnership 2014). The
media were incubated at 37 C and growth of MTB was observed
weekly for up to 6 weeks. Part of the deposit was inoculated on LJ
agar slants in 5 mL cryo-vials for shipment to a Supranational TB
Reference Laboratory (SRL) in Antwerp, Belgium for external
quality assurance. At the NTBRL, phenotypic culture and drug
susceptibility testing (CDST) was done on LJ on all MTB positive
isolates using the proportion method (Stop TB Partnership 2014).
First-line DST was done for the drugs streptomycin, isoniazid,
rifampicin and ethambutol (SIRE), and second-line DST for
kanamycin, amikacin, oﬂoxacin, moxiﬂoxacin and capreomycin.
All the isolates were stored at 20 C in cryo-vials with 10%
glycerol. Hain Line Probe assay (LPA) (Hain LifeSciences, Nehren,
Germany) was carried out on all cultures that failed to grow.
Discordances between Xpert MTB/RIF RR-TB results and ﬁrst-line
phenotypic DST were resolved by conventional Sanger DNA
sequencing of rpoB at the SRL. There was a 100% concordance in
sensitivity and speciﬁcity between NTBRL and the SRL on the drugs
kanamycin, capreomycin, oﬂoxacin and rifampicin. Sensitivity and
speciﬁcity of isoniazid were 90% and 89%, respectively.
Sampling
Sampling was done as per WHO guidelines (World Health
Organisation 2015a). First, probability proportional to size
sampling was used to select 63 of 146 national TB diagnostic sites
that were functional in 2012, and 20 of 56 national TB diagnostic
sites that became functional between 2012 and 2014. Within each
selected diagnostic site, consecutive eligible patients were
enrolled until the required number of new cases for that site
was reached, or the end of the survey period was reached.
As per WHO recommendations, sample size was calculated
based on new patients only; retreatment patients were sampled on
convenience. For new patients, a sample size of 677 was based on
the following assumptions: (i) a total national notiﬁcation of
12,405, based on 2012 programme data; (ii) an absolute precision
of 1% at 95% conﬁdence interval (CI); (iii) a priori estimated
prevalence of MDR-TB of 1.9%, based on the 1994 sub-national
survey. After factoring in a design effect of two and accounting for
possible losses of up to 20%, a minimum sample of 1625 new
smear-positive patients was estimated.
Survey and data management
A survey management team and a steering committee were
established to ensure smooth implementation of the survey. A pilot
survey was conducted in 10% of the sites. Three teams from the
national ofﬁce were trained and they later provided on-site
trainings to survey teams (TB nurses and laboratory staff) in
different provinces starting with low-volume sites.
Each recruiting facility maintained a survey register which
captured patient demographic and clinical data. Each patient had a
PIN which was linked to all the survey tools (survey register,
laboratory request form and NTBRL laboratory register). Xpert
MTB/RIF and CDST results were reported to facilities to inform
clinical management of patients. Quality of data was ensured
through training of survey teams, cross-checking original forms
during support visits by local teams and during data monitoring
missions supported by staff from WHO and KNCV.
De-anonymised data were sent to the central level by a courier
for double-data entry into the Census and Surveys Processing
System (CSPro) database by Zimbabwe National Statistics Agency
staff. Electronic data were stored in a password-protected
computer and backed-up on CDs stored in a locked-ﬁle cabinet.
Source documents were stored in locked-ﬁle cabinets (Table 1).
Data analysis
Data were exported to SPSS version 20 (Chicago, Illinois, USA)
for analysis. Categorical variables were summarized using
frequencies. Continuous variables were summarized using means
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and medians as appropriate. Weighted analysis of prevalence of
RR-TB and MDR-TB were done using exact sampling probabilities
to adjust for sampling error due to combining two sampling
methods and the capping of patient recruitment at 12 months.
Odds ratios and their 95% CI for factors associated with RR-TB were
calculated using the stepwise logistic regression. Level of signiﬁ-
cance was set at p < 0.05.
Ethics
This survey was approved by the Medical Research Council of
Zimbabwe and the Research Council of Zimbabwe. All the
participants provided written informed consent/assent prior to
enrolment and collection of sputum specimens.
Results
A total of 5279 sputum smear-positive patients were notiﬁed
during the survey period. Of these, 1301 (24.6%) were initially
enrolled and tested using Xpert MTB/RIF (Figure 1). Twenty-nine
patients (2%) were excluded due to lack of survey forms and/or
barcoding. The analysis population was 1272 patients: 1114 (87.6%)
new and 158 (12.4%) retreatment (Figure 1). Of these, 766 (60.2%)
were male, the median age was 34 years [(interquartile range (IQR),
27–42 years)], 699 (55.0%) self-reported a history of HIV infection,
and 765 (60.1%) were recruited from urban clusters (Table 2). A
total of 293 (23%) participants had a history of travel outside
Zimbabwe of one month’s duration.
Figure 1. Flow of participants who were enrolled in the Zimbabwe DRS 2015–2016.
MDR-TB = multi-drug resistant TB; FQ = Fluoroquinolone; XDR-TB = extensively drug resistant TB; RMR = rifampicin mono-resistant TB; Poly-resistant = resistance to >one
ﬁrst-line anti-TB drug, other than both isoniazid and rifampicin.
Table 1
Number and (proportion) of participants who were enrolled in the Zimbabwe Drug Resistant survey by province, 2015–16.
Province Total number notiﬁed during the survey period Number of new patients (%) Expected number of new patients
Total 5279 1114 (65.5) 1700
Manicaland 298 135 (79.4) 170
Mashonaland Central 250 138 (73.8) 187
Mashonaland East 304 78 (65.5) 119
Mashonaland West 282 133 (65.2) 204
Matabeleland North 152 71 (54.9) 153
Matabeleland South 328 83 (46.4) 119
Midlands 300 136 (88.9) 153
Masvingo 258 93 (60.8) 153
Harare 2879 166 (46.5) 357
Bulawayo 228 81 (95.3) 85
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Bacteriologic results
Of the 1272 valid Xpert MTB/RIF assays, 1184 (93.1%) detected
MTB. There were 44 (3.5%) new and 20 (1.6%) retreatment TB
patients who had Xpert-determined RR-TB. Of these 64, 50 (78.1%)
successfully grew on culture at the NTBRL. First and second-line
phenotypic DST conﬁrmed RR-TB in 48 (96%), while two cultures
(4%) were susceptible to all the ﬁrst-line drugs (SIRE) according to
phenotypic CDST, Hain LPA (at the NTBRL), and rpoB gene
sequencing at the SRL. Twenty-ﬁve cultures [(52.1%) (95% CI,
38.3, 65.5)] had MDR-TB; 20 demonstrated rifampicin mono-
resistance (RMR); three had poly-resistance and two were
rifampicin susceptible. Of the 25 MDR-TB cultures, one (4.0%)
demonstrated ﬂuoroquinolone and aminoglycoside resistance in
addition to MDR (XDR-TB).
The crude prevalence of RR-TB was [4.0% (95% CI, 2.9, 5.4%),
n = 42/1043] and [14.2% (95% CI, 8.9, 21.1%), n = 20/141] among
new and retreatment patients, respectively. The crude prevalence
of MDR-TB was 2.0% [(95% CI, 1.3, 3.1%)] and [6.4% (95% CI, 2.4,
10.3%)] among new and retreatment TB patients, respectively.
Among new patients, the weighted prevalence of RR-TB and MDR-
TB were [4.6% (95% CI, 3.0, 6.2)] and [1.8% (95% CI, 1.0, 2.5)]
respectively.
Risk factors for RR-TB
In univariate analysis, a history of travel outside Zimbabwe for
one month [(odds ratio [(OR = 1.74, 95% CI, 1.02, 2.97)] had
increased odds of RR-TB. In multivariate analysis, HIV-positivity
[adjusted odds ratio (aOR) = 2.12 (95% CI, 1.09, 4.05)], age <15 years
[aOR = 6.37 (95% CI, 1.51, 26.87)], and a previous history of TB
treatment [aOR = 3.53 (95% CI,1.86, 6.25)] were associated with RR-
TB, while having at least a secondary education was protective
[(aOR = 0.52; 95% CI, 0.29, 0.97)] (Table 3). After stratifying by type
of TB patient, a positive HIV status [aOR = 2.19; 95% CI, 1.07, 4.46)]
and history of travel outside Zimbabwe [aOR = 2.05; 95% CI, 1.05,
4.03)] were signiﬁcantly associated with RR-TB among new
patients (Table 4).
Table 2
Socio-demographic and clinical characteristics of patients enrolled in the Zimbabwe TB drug resistant survey, 2015–2016.
Demographic characteristics TB patients Total
New Retreatment
n (%) n (%) n (%)a
Total 1114 (87.6) 158 (12.4) 1272
Sex
Male 668 (60.0) 98 (62.0) 766 (60.2)
Female 446 (40.0) 60 (38.0) 506 (39.8)
Age group
<15 18 (1.6) 1 (0.6) 19 (1.5)
15–24 171 (15.4) 13 (8.2) 184 (14.5)
25–34 415 (37.3) 43 (27.2) 458 (36.0)
35–44 315 (28.3) 50 (31.6) 365 (28.7)
45–54 116 (10.4) 33 (20.9) 149 (11.7)
55–64 46 (4.1) 7 (4.4) 53 (4.2)
65 31 (2.8) 11 (7.0) 42 (3.3)
Unknown 2 (0.2) 0 (0) 2 (0.2)
HIV status
Positive 580 (52.1) 119 (75.3) 699 (55.0)
Negative 492 (44.2) 34 (21.5) 526 (41.4)
Unknown 42 (3.7) 5 (3.2) 47 (3.6)
History of any travel outside Zimbabwe
For 1 month 243 (21.8) 50 (31.6) 293 (23.0)
To South Africa 166 (14.9) 32 (20.3) 198 (15.6)
Other SADC countries 62 (5.6) 17 (10.8) 79 (6.2)
To other SADC countries 8 (0.7) 1 (0.6) 9 (0.7)
Unknown 7 (0.6) 0 (0.0) 7 (0.6)
Marital status
Never married 229 (20.6) 22 (13.9) 251 (19.7)
Married 600 (53.9) 75 (47.5) 675 (53.1)
Divorced 177 (15.9) 33 (20.9) 210 (16.5)
Widowed 89 (8.0) 22 (13.9) 111 (8.7)
Unknown 19 (1.7) 6 (3.8) 25 (2.0)
Level of education
None 39 (3.5) 4 (2.5) 43 (3.4)
Primary 312 (28.0) 46 (29.1) 358 (28.1)
Secondary 700 (62.8) 94 (59.5) 794 (62.4)
Tertiary 55 (4.9) 13 (8.2) 68 (5.3)
Missing 8 (0.7) 1 (0.6) 9 (0.7)
Cluster location
Urban 671 (60.2) 94 (59.5) 765 (60.1)
Rural 443 (39.8) 64 (40.5) 507 (39.9)
SADC = Southern Africa Development Community; TB = tuberculosis.
a Column percentages.
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Table 3
Risk factors for rifampicin resistance among patients diagnosed with smear-positive sputum during the TB drug resistant survey, Zimbabwe (2015–2016).
Variable Total RR-TB detected OR (95% CI) aOR 95% CI
n (%)a
1184 62 (5.2)
Sex
Female 466 20 (4.3) Ref Ref
Male 718 42 (5.8) 1.38 (0.78, 2.52) 1.43 (0.69, 2.46)
Age group
<15 18 4 (22.2) 6.90 (1.80, 26.45)b 6.37 (1.51, 26.87)b
15–24 176 7 (4.0) Ref Ref
25–34 431 19 (4.4) 1.11 (0.46, 2.70) 0.96 (0.38, 2.42)
35-44 337 22 (6.5) 1.68 (0.68, 4.77) 1.25 (0.46, 3.27)
45–54 128 5 (3.6) 0.91 (0.28, 2.92) 0.52 (0.16, 1.75)
55–64 48 3 (6.2) 1.61 (0.40, 6.47) 1.04 (0.24, 4.42)
65 34 2 (5.9) 0.51 (0.30, 7.60) 0.90 (0.16, 4.98)
Level of education
Primary and less 363 27 (7.4) Ref Ref
Secondary and above 813 34 (4.2) 0.54 (0.31, 0.95)b 0.52 (0.29, 0.97)b
Unknown 8 1 (12.5) 1.78 (0.21, 14.99) 2.83 (0.30, 27.08)
Cluster location
Urban 714 37 (5.2) Ref
Rural 470 25 (5.3) 1.03 (0.58, 1.78) 0.90 (0.54, 1.71)
HIV status
Negative 508 14 (2.8) Ref Ref
Positive 632 46 (7.3) 2.77 (1.46, 5.52)b 2.12 (1.09, 4.05)b
Unknown 44 2 (4.5) 1.68 (0.18, 7.70) 1.34 (0.29, 6.24)
History of any travel outside Zimbabwe
for 1 month 281 22 (7.8) 1.74 (1.02, 2.97)b 1.69 (0.95, 2.99)
To South Africa 190 17 (8.9) 1.55 (0.55, 4.36) 1.49 (0.57, 4.39)
To other SADC countries 270 21 (7.8) 0.84 (0.10, 6.91) 0.87 (0.15, 6.42)
Treatment history
New 1043 42 (4.0) Ref Ref
Retreatment 141 20 (14.2) 3.94 (2.11, 7.11)b 3.53 (1.86, 6.25)b
OR = odds ratio; HIV = human immune-deﬁciency virus; aOR = adjusted odds ratio; SADC = Southern Africa Development Community; Ref = reference.
a Row percentages.
b Signiﬁcant.
Table 4
Factors associated with rifampicin resistance, among patients diagnosed with smear-positive sputum during the TB drug resistant survey, Zimbabwe (2015–2016),
disaggregated by type of TB patient.
Risk factors Type of TB case
New (n = 1043) Retreatment (n = 141) Total (n = 1184)
aOR 95% CI aOR 95% CI aOR 95% CI
Sex
Female 1.08 0.55, 2.12 2.16 0.68, 6.82 1.43 0.69, 2.46
Male Reference Reference Reference
Age group
<15 8.59 1.47, 50.04a – 6.37 1.51, 26.87a
15–24 Reference Reference Reference
25–34 1.62 0.45, 5.84 0.28 0.05, 1.48 0.96 0.38, 2.42
35–44 2.44 0.68, 8.77 0.29 0.06, 1.40 1.25 0.46, 3.27
45–54 0.64 0.10, 4.06 0.19 0.03, 1.11 0.52 0.16, 1.75
55–64 2.43 0.45,13.27 N/A 1.04 0.24, 4.42
65 1.91 0.19,19.80 0.20 0.02, 2.56 0.90 0.16, 4.98
Level of education
Primary Reference Reference Reference
Secondary 0.52 0.27, 1.02 0.75 0.21, 2.67 0.52 0.29, 0.97a
Unknown 5.11 0.51, 51.25 – 2.83 0.30, 27.08
HIV status
Negative Reference Reference Reference
Positive 2.19 1.07,4.46a 1.76 0.44, 7.09 2.12 1.09, 4.05a
Unknown 0.89 0.11, 7.25 2.72 0.21,34.71 1.34 0.29, 6.24
History of travel outside Zimbabwe
for  1 month 2.05 1.05,4.03a 1.09 0.37, 3.16 1.69 0.95, 2.99
Treatment history
New Reference
Re-treatment 3.53 1.86, 6.25a
OR = odds ratio; HIV = human immune-deﬁciency virus; aOR = adjusted odds ratio. – = undeﬁned.
a Signiﬁcant.
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Discussion
This ﬁrst nationally representative TB-DRS survey for
Zimbabwe was conducted following signiﬁcant socio-political
and epidemiological changes in the country. We demonstrated that
the prevalence of MDR-TB has remained stable since 1994 though
the prevalence of RR-TB is now double that of MDR-TB. We also
observed that the factors associated with RR-TB were a previous
history of TB, HIV positivity, age <15 years, lower than secondary
education and a stay outside Zimbabwe for a month.
The observed prevalence of MDR-TB was consistent with
prevalence reported from South Africa [(2.1% (95% CI, 1.5, 2.7)
and 4.6% (CI, 95%: 3.2, 6.0) among new and previously treated
patients, respectively in the 2012–2014 survey] and Botswana
[(2.5%, 95% CI, 1.6, 3.7) and 6.6%, 95% CI, 3.3, 11.7) among new and
previously treated patients during 2007–2008)] (National Institute
for Communicable Diseases 2014; Menzies et al. 2014), but was
lower than prevalence recorded in both Lesotho [(3.1% (95% CI, 2.1,
4.3) and (12.8% (95% CI, 8.8, 18.2)] among previously treated
patients and Namibia [(3.8% (95% CI, 2.8, 5.1) and (16.4% (95% CI,
12.9, 20.6)] among previously treated patients for the survey
carried out in 2008–2009 (Maama-Maime et al. 2015; Ministry of
Health and Social Services: National Tuberculosis and Leprosy
Programme 2012). The increase in the prevalence of RR-TB could be
attributed to a high proportion of RMR observed in this study. This
may be due to acquired resistance to rifampicin. Studies have
shown associations between RMR and factors like a positive HIV
status, previous histories of TB, use of antifungals and use of
rifabutin (Meyssonnier et al. 2014; Ridzon et al. 2013; Villegas et al.
2016). The association between a positive HIV-status and RR-TB
could be attributed to acquired drug resistance resulting from
“preferential adherence” to antiretroviral drugs at the expense of
anti-TB drugs among TB co-infected patients as reported in a
previous qualitative study (Daftary et al., 2014).
The ﬁndings that the previous histories of TB and stay outside
Zimbabwe for 1 month (bivariate analysis) were associated with
RR-TB were not surprising. The latter may stem from the fact that
most Zimbabweans go to neighbouring, high TB-burden countries
as economic emigrants and living conditions there may foster
acquisition of RR-TB. Neither DRS surveys in southern Africa nor
studies, including systematic reviews, found any association
between MDR-TB and HIV infection (Lukoye et al. 2015; National
Institute for Communicable Diseases 2014; Maama-Maime et al.
2015; Ministry of Health and Social Services: National Tuberculosis
and Leprosy Programme 2012; Menzies et al. 2014).
We do not know the reasons why attainment of secondary
education was protective against RR-TB. Perhaps, attainment of
secondary education is associated with better socio-economic
status and positive health behavioral traits. By contrast, a study
done in China showed that attainment of high school was a risk
factor for RR-TB (Yang et al. 2015). Drug resistant surveys from
southern Africa did not assess the relationship between education
and risk of RR-TB. Studies from high-income countries failed to
show the relationship between education and risk of RR-TB. Thus
more research is needed to investigate this relationship.
This study enrolled more patients from urban than from rural
areas, a consistent ﬁnding with program data in which high
notiﬁcations are recorded in urban centers. This exposes geo-
graphical health inequities despite a similar burden of MTB
between rural and urban centers as evidenced in this study and the
2014 Zimbabwe National TB prevalence survey (Ministry of Health
and Child Care 2014).
This survey had some limitations. First, in adopting sputum
smear-positivity as our starting point, we invariably underreported
RR-TB in this high HIV-burden setting given that children and HIV-
positive patients often produce pauci-bacillary specimens. Second,
all sputum specimens in which RR-TB was not detected did not
undergo CDST. Thus, the prevalence of isoniazid mono-resistance
is unknown, though it is known to be rising elsewhere in the
southern Africa Development Community (SADC) (Variava and
Martinson 2018; National Institute for Communicable Diseases
2014). Future DRS surveys should determine the prevalence of
isoniazid-mono resistance. Third, 6% of new and 11% of retreat-
ment sputum smear-positive specimens tested Xpert MTB/RIF-
negative, raising the possibility of non-tuberculosis mycobacteria
(NTM). Indeed the previn adopting sputum smear-positivity as our
starting point, we invariably underreported RR-TB in this high HIV-
burden setting given that children and HIV-positive patients often
produce pauci-bacillary specimens. Second, all sputum specimens
in which RR-TB was not detected did not undergo CDST. Thus, the
prevalence of isoniazid mono-resistance is unknown, though it is
known to be rising elsewhere in the southern Africa Development
Community (SADC) (Variava and Martinson 2018; National
Institute for Communicable Diseases 2014). Future DRS surveys
should determine the prevalence of isoniazid-mono resistance.
Third, 6% of new and 11% of retreatment sputum smear-positive
specimens tested Xpert MTB/RIF-negative, raising the possibility of
non-tuberculosis mycobacteria (NTM). Indeed the prevalence of
NTM is very high in Zimbabwe. During the 2014 TB prevalence
survey the prevalence of NTM was estimated to be 16.9% (964/
5705) of all the survey presumptive TB cases. Of the NTM isolates
obtained in a convenient sample of specimens collected during the
2014 TB prevalence survey, the prevalence of clinically signiﬁcant
NTM such as Mycobacteria Avium complex (MAC) was 51.5% (41/81)
(Chin’ombe et al. 2016; Ministry of Health and Child Care 2014).
Fourth, HIV status was obtained by self-report. Incorporation of
HIV testing in TB-DRS surveys could have provided crucial
information for the NTP on the relationship between HIV and
drug-resistant TB (World Health Organization 2015). Lastly, we did
not do multiple imputation to control for bias on the results for 14
samples that did not have DST results (no culture growths or
contaminated cultures) since our data were robust. However, it
would have been a useful exercise to compare potential differences
in results between our models and the imputation models.
Several programmatic implications arise from this study. First,
there is need to improve early and universal access to DST (in
Zimbabwe and elsewhere in SADC) for at least rifampicin, in line
with the WHO End TB strategy (STOP TB Partnership 2015). Second,
since isoniazid prophylactic therapy (IPT) has been scaled up in
Zimbabwe with 20,000 PLHIV having been started on IPT by
December 2015 and IPT completion rates of 89% have been
attained (Takarinda et al. 2017, 2019), and within the context of
South African isoniazid-mono resistance of [4.9%, 95% CI: 4.1%–
5.8%)],(National Institute for Communicable Diseases 2014)
estimating the prevalence of and continued monitoring of
isoniazid mono-resistance should be prioritized in Zimbabwe.
Third, although sample size was small and should be interpreted as
hypothesis-generating, we noted an increased risk of RR-TB among
older children and adolescents, and warrants additional studies
examining the determinants of childhood RR-TB in Zimbabwe.
Lastly, we could not follow up on the treatment outcomes of this
group.
In conclusion, the prevalence of MDR-TB in Zimbabwe has
remained stable since the 1994 subnational survey.
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